Horizon Pharma Inc. (Nasdaq: HZNP) is buying Vidara Therapeutics International Ltd. in a deal valued at $660 million.

Vidara, headquartered in Dublin, is a specialty pharmaceutical company that makes Actimmune, a drug approved by the U.S. Food and Drug Administration that is used in patients with chronic granulomatous disease and osteopetrosis.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.